Managing Trodelvy’s Side Effects Through Dose Adjustment

Trodelvy (sacituzumab govitecan), the standard treatment for triple-negative breast cancer, offers hope for improved survival, but comes with the challenge of managing side effects, as an expert explained to CURE® during an interview.

Real-world data has confirmed Trodelvy’s effectiveness in treating metastatic triple-negative breast cancer. This real-world evidence, published in JCO Oncology Practice, demonstrates the drug’s clinical benefit and side effect manageability in a diverse patient population allowing for more applicable results.

READ MORE: Trodelvy Is Effective in Real-World Patients With Breast Cancer Subset

While side effects like neutropenia, anemia and fatigue are common, they are often manageable. Trodelvy offers a valuable treatment option for patients with limited therapeutic choices, as mentioned.

CURE spoke with Dr. Arya Roy, a breast medical oncology and assistant professor at The Ohio State Comprehensive Cancer Center, to learn more about the treatment benefits and side effect management with Trodelvy for those with triple-negative breast cancer.

Transcript:

So Trodelvy has side effects which are actually usually manageable in the clinic. And there is one more thing. You can dose reduce Trodelvy if it's needed. So, the usual dose is 10 milligram per kilogram. That's the dose that is approved to be used by the FDA.

But lot of the times, I actually dose reduce it when I start the patient on treatment, especially if they are more than 60 years old, [and] especially if they are neutropenic to begin with, or if they had a lot of treatments in the past, I dose reduce the treatment to begin with, and then if they don't have any problems with neutropenia or the side effects with Trodelvy, I increase their dose back up to the normal level.

And we also found that in our study that even if we decrease the dose of Trodelvy for the first few cycles, it will not affect the efficacy of the drug. So, it gives you like same benefit in terms of efficacy, but less side effects.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.